Pediatric Atopic Dermatitis: Clinical Scenarios – Clinical Brief #2


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


It’s estimated that 30% of the approximately 9.6 million American children with atopic dermatitis (AD) suffer from moderate to severe disease. “Suffer” is the operative word, as the disease has a wide range of deleterious effects, including unrelenting itch and sleep disturbance. When suboptimally treated, this can lead to learning disabilities and behavioral disorders resulting in long-term impact on education and psychosocial health. However, medical science is rapidly unraveling the pathogenic molecular drivers of this disease and a variety of targeted treatments have recently been approved to treat children, adolescents, and even infants with moderate to severe AD.

Join us for this Twitter-based Clinical Brief with experts Drs. Peter Lio, Robert Sidbury, Colleen Cotton, and Shawn Kwatra as they discuss managing adolescents with moderate to severe AD.


Peter A. Lio, MD  
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Robert Sidbury, MD, MPH 
Department of Pediatrics
University of Washington School of Medicine
Division Chief, Dermatology
Seattle Children’s Hospital
Seattle, Washington


Colleen Cotton, MD, FAAD
Assistant Professor of Dermatology and Pediatrics
George Washington School of Medicine and Health Sciences
Attending Physician
Division of Dermatology, Children’s National Hospital
Washington, District of Columbia

Shawn Kwatra, MD 
Director, Johns Hopkins Itch Center
Associate Professor of Dermatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Release date: May 24, 2023
Expiration date: August 24, 2023
Estimated time to complete activity: 15 minutes

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with AD.


Upon completion of this educational activity, participants should be able to:

  • Describe the impact of moderate to severe AD on behavior, psychological health, and overall quality of life

There are no fees for participating and receiving CME credit for this activity. During the period of May 24, 2023 through August 24, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Colleen Cotton, MD, FAAD
Advisory Boards: Avita, Bristol Myers Squibb, Janssen Biotech, LEO Pharma
Consultant: Pierre Fabre
Salary Support: Eli Lilly, Regeneron, Target RWA
Speaker: Bayer, United Therapeutics
Research: AbbVie, Arcutis Biotherapeutics

Shawn Kwatra, MD
Consultant: AbbVie, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Castle Bioscience, Celldex Therapeutics, Novartis
Investigator: Incyte, Pfizer, Regeneron, Sanofi,

Peter Lio, MD
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burts Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin, Micreos, YobeeCare

Robert Sidbury, MD, MPH
Consultant: Eli Lilly, LEO
Research: Castle, Galderma, Pfizer, Regeneron, UCB
Speaker: Biersdorf

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest